Anti-Gal3 Antibodies for Disrupting Insulin Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes mellitus, inflammatory bowel disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis are inadequate, with a need for effective pharmaceutical interventions, particularly targeting the interactions between Galectin-3 and insulin receptor or integrins.
Innovation Solution
Development of anti-Galectin-3 antibodies or binding fragments that selectively disrupt the interaction between Galectin-3 and insulin receptor or integrins, administered to subjects to treat these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diabetes mellitus and liver diseases are used, then existing therapeutic options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent uses anti-Galectin-3 antibodies as intermediary molecules to block the interaction between Galectin-3 and insulin receptor/integrins. The antibody serves as a mediator that binds to Galectin-3 and prevents it from interacting with its target proteins, thereby treating diabetes and liver diseases without directly modifying the target proteins themselves.
2Reliability
If Galectin-3 interaction with insulin receptor is blocked, then insulin resistance is reduced, but new therapeutic mechanism is required
Solution Approach 1:
The patent extracts and neutralizes the harmful interaction between Galectin-3 and insulin receptor by introducing antibodies that specifically bind to Galectin-3. This removes the pathological binding event without requiring modification of the insulin receptor itself, thereby improving insulin sensitivity through a targeted intervention.
3Object-affected harmful factors
If Galectin-3 interaction with integrins is disrupted, then inflammation is reduced, but selective binding capability is needed
Solution Approach 1:
The patent employs antibodies with specific binding characteristics that target Galectin-3 at particular epitopes. The CDR regions of the antibodies are designed to recognize and bind selectively to specific regions on Galectin-3, ensuring localized and selective disruption of the Galectin-3-integrin interaction while minimizing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively reduce insulin resistance, weight gain, liver steatosis, and inflammation, providing therapeutic benefits for diabetes, inflammatory bowel disease, and liver diseases by disrupting harmful interactions.
Implementation Method 1
contacting an interaction between Gal3 and the insulin receptor or the integrin, or both, with an anti-Gal3 antibody or binding fragment thereof that selectively binds to Gal3 and disrupts the interaction between Gal3 and the insulin receptor or the integrin
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.